In the re-examination of US Patent No. 6,711,426, the Patent Office has affirmed that Spectros’ use of White LEDs in medical spectroscopy is protectable, and that certain other applications in biomedical and industrial spectroscopy devices also fall under this Spectros patent.
Spectros CEO David Benaron said this is a broad affirmation of their dominant IP in the white LED and broadband spectroscopy area.
"This will serve as the basis for our expansion into lab-on-chip devices, color sensors, spectrometers, fluorimeters, and white LED pulse and tissue oximeters," Benaron said.
Spectros markets and licenses molecular sensing and imaging devices that shed light on ischemia and cancer.
Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute.
